Prof. Mehmet Haberal is presented with The Award of The Spanish Order of The Civil Merit (Cruz de Official) by His Majesty King Felipe VI, King of Spain.
His Majesty King Felipe VI, King of Spain, bestowed upon Professor Mehmet Haberal the award of The Spanish Order of the Civil Merit (Cruz de Official) in recognition to the professional career of Professor Haberal in the fields of Medicine and Education.
The award ceremony was held on Thursday, February 20th, 2020 at Baskent University campus in Ankara with the participation of former and current parliament members, Ambassadors of various countries, Mayor of Ankara, respected authorities, Baskent University members as well as representatives from the Press.
The award was presented by Chargé d’Affaires a.i. of Spain, Mr. Eduardo Ibañez López-Dóriga, to convey public recognition to the exceptional scientific and medical career of Professor Haberal and, through him, to that of so many other that have contributed to the prestige of Turkish Science and medicine in the world.
Professor Haberal has been heralded as a pioneer in the fields of general surgery, transplantation, and burn treatment in Turkey and the world since 1975 and is renowned internationally in the medical community. He performed the first living-related kidney transplantation in Turkey on November 3, 1975, the first cadaver-kidney transplantation in Turkey on October 10, 1978, with a kidney donated by Eurotransplant, and the first domestic cadaver-kidney transplantation in Turkey on July 27, 1979, immediately after enabling the laws on harvesting, storage, grafting, and transplantation of organs and tissues to be enacted on June 3, 1979. He is the first person to perform the first successful cadaver-liver transplantation in Turkey, in the Middle East and in Northern Africa on December 8, 1988. Professor Haberal followed this on March 15, 1990 with the first pediatric segmental living-related liver transplantation in Turkey, the region, and in Europe immediately succeeded by the first adult segmental living-related liver transplantation (left lobe) in the world on April 24, 1990. On May 16, 1992, Professor Haberal performed combined liver-kidney transplantation from a living-related donor, which was the first operation of its kind anywhere in the world.
Spain is the world leader in the field of organ transplantation and organ donation for the last 27 years, and 2243 people in Spain became deceased organ donors last year. That is 48.0 per million people in the population (pmp) which made 5.314 transplant surgeries possible. During his speech, Mr. Eduardo Ibañez López-Dóriga highlighted the importance of deceased organ donation and emphasized that as being the world leader in organ transplantation, it is a natural fact that Spain would like to praise Professor Haberal for his contributions to organ donation and transplantation worldwide.
The IPTA Outreach Committee is pleased to announce that applications for the 2020 Outreach Program are open. The program supports emerging centres that seek to develop or expand/enhance care in existing transplant programs.
Usually, an emerging centre will have identified a suitable supporting centre to assist them with this program; however it is possible the Outreach Committee can assist in this process.
The application package, guidelines and useful reference documents are available on the Outreach Program section of the IPTA website.
With many thanks,
Chair, IPTA Outreach Committee
Dr. Andrea Schlegel, Editorial Fellow, Transplantation
Han F, Wan S, Sun Q, et al.
Transplantation: November 2019 - Volume 103 - Issue 11 - p 2347-2358
The important role of mitochondria is increasingly discussed in context of ischemia-reperfusion injury during transplantation of all solid organs. Such cellular powerhouses are now also in focus for their release of various proteins and molecules when injury occurs in organs or tissues. Authors from China have assessed if the release of mitochondrial DNA (mtDNA) in organ donors could serve as useful marker to predict kidney function and recovery after transplantation. For this purpose, mitochondrial DNA was quantified in donor plasma and correlated with proximal tubular injury assessed through KIM-staining’s in time zero kidney biopsies. In contrast to other parameters, including donor creatinine, the kidney donor profile index (KDPI), or donor warm ischemia time, the amount of circulating mtDNA in donor plasma correlated well with early kidney function and discriminated recipients, who experience delayed or even non-function from others with immediate graft function. Importantly, recipients of kidneys from donors with low levels of mitochondrial DNA had a significantly better graft survival. The amount of plasma mtDNA appears relatively easy to detect during donor evaluation and predicts kidney function and survival after transplantation. This mitochondrial marker could serve as novel tool to predict kidney viability and is currently evaluated in other organs in the same context.
We have an opening for Vice President (2020-2024) due to current Vice President running unopposed for the position of President-Elect. The nomination period will be open for two weeks.
In order to help young members offset expenses to attend our Congress in Seoul, TTS 2020 will be offering Young Investigator Awards and International Transplantation Science Mentee-Mentor Awards. Award recipients will be selected on scientific merits (TTS 2020 Scientific Program Committee is extending the abstract submission deadline to Tuesday, March 3, 2020 at 23:59 EST due to the general demand from the transplantation community).
To be eligible for the Young Investigator Awards, you need to apply by March 23, 2020, submit an abstract to the Congress, be a trainee (within 2 years of completion of their training and/or fellowship) and be a member of TTS.
TTS in collaboration with National and International Societies acknowledges the contribution of basic science to the field of transplantation by offering Mentee-Mentor awards.
To be eligible, you need to apply by March 23, 2020, submit an abstract to the Congress, be a graduate student or trainee (within 5 years of receiving PhD, MD), both Mentee and Mentor must attend TTS 2020 and be member of both TTS and confirmed supporting Societies.
The Allied Health Provider Committee of IRTA is pleased to present the first webinar of the Allied Health 2020 Speaker Series. This webinar will focus on patient care strategies and outcomes within intestinal rehabilitation and transplant. The topics presented will provide updates focusing on nutritional interventions and physical outcomes in intestinal failure as well as analgesia post-intestine transplant. Each presentation will be 15 minutes in length followed by a 5-minute question period.
Feb. 21 - Heart disease is the primary cause of death worldwide, principally because the heart has minimal ability to regenerate muscle tissue. Although cell therapy is feasible and largely safe, randomized, controlled trials in patients show little consistent benefit from any of the treatments with adult-derived cells. In the meantime, pluripotent stem cells have produced bona fide heart muscle regeneration in animal studies and are emerging as leading candidates for human heart regeneration.
Feb. 21 - Myeloablative conditioning (MAC) led to a long-term survival benefit versus reduced-intensity conditioning (RIC) for patients with acute myeloid leukemia (AML) treated with hematopoietic cell transplantation, updated results from a randomized trial showed.
Feb. 21 - Acute graft-versus-host disease tended to be less severe among patients who underwent haploidentical transplantation with post-cyclophosphamide prophylaxis than those who underwent 8/8 HLA-matched unrelated donor stem cell transplant with standard prophylaxis, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings.
Feb. 19 - Higher total body irradiation dose appeared associated with significantly higher risk for nonrelapse mortality and overall mortality among patients with non-Hodgkin lymphoma who underwent reduced-intensity conditioning prior to allogeneic hematopoietic stem cell transplantation, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings.
Feb. 21 - Preliminary results of the phase III SIERRA trial indicate that conditioning therapy with iodine apamistamab (Iomab-B) leads to high rates of allogeneic hematopoietic stem cell transplant (HCT) in patients with active acute myeloid leukemia (AML), according to Boglarka Gyurkocza, MD, who presented midpoint results of the trial at the 2020 Transplant & Cellular Therapies Meeting in Orlando, Florida.
It is our great honor and privilege to welcome you to the Symposium on “Deceased Organ Donation and Religion” on March 12-13, 2020 in Ankara, Turkey.
Organ transplantation is accepted as a valid and advanced treatment method applied in many chronic organ diseases. However, millions of people die and are buried with healthy organs, which could save the lives of many patients who continue to wait on Transplant lists. Unfortunately, organ shortage is the greatest challenge facing the field of organ transplantation today.
Our aim as the transplant community should be to work towards a system of meeting the organ demand entirely with deceased organ donation. This will make an enormous difference to those patients awaiting transplants in which living organ donors are not an option.
However, cultural and religious beliefs play an important role in organ transplantation activities worldwide. In order to effectively continue to make the best use of the opportunities we have today, it is essential that we discuss the issue from the perspectives of different religions and explore ways to solve the problems caused by this issue.
In the light of these, we have decided to organize a Symposium on “Deceased Organ Donation and Religion” on March 12-13, 2020 in Ankara, Turkey. The Symposium will be held at the Baskent University Campus in Ankara to ensure our young colleagues and students are participated at the highest level.
We are delighted to welcome you to Ankara, Turkey for this Symposium, and we hope you enjoy the scientific sessions and the social events we have planned.
Mehmet Haberal, MD, FACS (Hon), FICS (Hon),
FASA (Hon), FIMSA (Hon), Hon FRCS (Glasg)
President, The Transplantation Society
Founder and Founder President, Baskent University
President of the Executive Supreme Board, Baskent University
Chair, Baskent University Division of Transplantation
Chair, Deceased Organ Donation and Religion International Symposium
We are excited to announce that the planning for the Chauvet 2020 meeting is well underway. This meeting is of interest to all health care providers who care for individuals with upper extremity amputations, severe facial disfigurement, absolute uterine factor infertility and those with loss of laryngeal function and all VCA candidates and recipients. If you are in any discipline with an interest in the psychosocial aspects of these patients, this meeting will interest you.
Email us to add yourself to our mailing list or with questions at firstname.lastname@example.org.
Watch for links to more information coming soon!